0001181431-13-052511.txt : 20131003 0001181431-13-052511.hdr.sgml : 20131003 20131003210152 ACCESSION NUMBER: 0001181431-13-052511 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20131001 FILED AS OF DATE: 20131003 DATE AS OF CHANGE: 20131003 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: ONYX PHARMACEUTICALS INC CENTRAL INDEX KEY: 0001012140 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 943154463 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 249 E. GRAND AVE. CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 650-266-0000 MAIL ADDRESS: STREET 1: 249 E. GRAND AVE. CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: LUNDBERG MAGNUS CENTRAL INDEX KEY: 0001235944 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-28298 FILM NUMBER: 131135349 4 1 rrd392206.xml FORM 4 X0306 4 2013-10-01 1 0001012140 ONYX PHARMACEUTICALS INC ONXX 0001235944 LUNDBERG MAGNUS C/O ONYX PHARMACEUTICALS, INC. 249 E. GRAND AVE. SOUTH SAN FRANCISCO CA 94080 1 0 0 0 Common Stock 2013-10-01 4 U 0 12116 125.00 D 2100 D Common Stock 2013-10-01 4 D 0 2100 125.00 D 0 D Stock Options 31.70 2013-10-01 4 D 0 10000 0 D 2008-06-08 2017-06-08 Common Stock 10000 0 D Stock Options 33.70 2013-10-01 4 D 0 10000 0 D 2009-06-09 2018-06-09 Common Stock 10000 0 D Stock Options 28.55 2013-10-01 4 D 0 4041 0 D 2010-03-31 2019-03-31 Common Stock 4041 0 D Stock Options 30.28 2013-10-01 4 D 0 5000 0 D 2011-03-31 2020-03-31 Common Stock 5000 0 D Stock Options 35.18 2013-10-01 4 D 0 5000 0 D 2012-03-31 2021-03-31 Common Stock 5000 0 D Stock Options 37.68 2013-10-01 4 D 0 5000 0 D 2013-03-30 2022-03-30 Common Stock 5000 0 D Stock Options 76.79 2013-10-01 4 D 0 2000 0 D 2013-07-25 2022-07-24 Common Stock 2000 0 D Stock Options 88.86 2013-10-01 4 D 0 5900 0 D 2014-03-28 2023-03-27 Common Stock 5900 0 D These restricted stock awards were cancelled at the effective time of the merger (the "Merger") pursuant to the Agreement and Plan of Merger, dated August 24, 2013, by and among Onyx Pharmaceuticals, Inc. ("Onyx"), Amgen Inc. and Arena Acquisition Company (the "Merger Agreement") in exchange for an aggregate cash payment equal to the number of shares of Onyx's common stock underlying such restricted stock awards multiplied by the per share purchase price of $125.00. Represents options to purchase Onyx's common stock that were subject to vesting over time but were cancelled in the Merger in exchange for a cash payment in the amount by which the per share purchase price of $125.00 exceeded the exercise price of the option as of the effective time of the Merger. /s/ Matthew K. Fust, Attorney-in-fact 2013-10-03